Adriano De-Souza-Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adriano De-Souza-Silva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adalberto Vieyra
Graduate Program in Translational Biomedicine/BIOTRANS UNIGRANRIO University Duque de Caxias Brazil
1 shared publication - Ana Angelica Celso de Lima Barreto da Silva
Leopoldo de Meis Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21590-902, Brazil
1 shared publication - Claudia Fernanda Dick
Leopoldo de Meis Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21590-902, Brazil
1 shared publication - Giovanna Frechiani
Graduate Program in Translational Biomedicine/BIOTRANS, Grande Rio University/UNIGRANRIO, Duque de Caxias 25071-202, Brazil
1 shared publication - Ian H. Gilbert
University of Dundee
1 shared publication - José Roberto Meyer-Fernandes
Instituto de Bioquímica Médica Leopoldo de Meis, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, RJ, Brazil
1 shared publication
Latest Publications
- Open Access
Impacts of Cipargamin on Na+-ATPase and Osmoregulation of Trypanosoma cruzi
The subfamily ENA of the P-ATPases family transports Na+ and H+ in opposite directions and, for this reason, they are called Na+-ATPases. They are physiologically important at high pH and high salt conditions in which other Na+ transporters cannot operate. This is the case, for example, of Aspergilus and Arabidopsis, respectively. Since, during their lifecycle, the parasitic protozoa face alkaline and/or high-saline environments, we postulated that the ENA subfamily could be a target for the treatment of serious and common illnesses driven by parasitic protozoa, as in the case of Chagas disease. The subgroup ATP4 ATPases, which is found in Plasmodium falciparum and Toxoplasma gondii, can be compared —through phylogenetic analysis—with the classic IID P-type ENA subfamily. Thus, some drugs that target PfATP4 ATPase and affect Na+ homeostasis are undergoing clinical trial, including spiroindolones. ENA-type ATPases (P-type ATPase IID) and ATP-type ATPase do not have structural homologs in mammals, appearing only in plants, fungi, and protozoan parasites, such as Trypanosoma cruzi, Leishmania sp., T. gondii, and P. falciparum. Therefore, this exclusivity points to Na+-ATPases as promising targets for medical projects aiming at new treatments contributing to the academic community.
Open AccessImpacts of Cipargamin on Na+-ATPase and Osmoregulation of Trypanosoma cruzi
The subfamily ENA of the P-ATPases family transports Na+ and H+ in opposite directions and, for this reason, they are called Na+-ATPases. They are physiologically important at high pH and high salt conditions in which other Na+ transporters cannot operate. This is the case, for example, of Aspergilus and Arabidopsis, respectively. Since, during their lifecycle, the parasitic protozoa face alkaline and/or high-saline environments, we postulated that the ENA subfamily could be a target for the treatment of serious and common illnesses driven by parasitic protozoa, as in the case of Chagas disease. The subgroup ATP4 ATPases, which is found in Plasmodium falciparum and Toxoplasma gondii, can be compared —through phylogenetic analysis—with the classic IID P-type ENA subfamily. Thus, some drugs that target PfATP4 ATPase and affect Na+ homeostasis are undergoing clinical trial, including spiroindolones. ENA-type ATPases (P-type ATPase IID) and ATP-type ATPase do not have structural homologs in mammals, appearing only in plants, fungi, and protozoan parasites, such as Trypanosoma cruzi, Leishmania sp., T. gondii, and P. falciparum. Therefore, this exclusivity points to Na+-ATPases as promising targets for medical projects aiming at new treatments contributing to the academic community.
- Open Access
- 21 January 2011
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 10 (1) , 3
Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis
Background: Sterol biosynthesis is an essential pathway for fungal survival, and is the biochemical target of many antifungal agents. The antifungal drugs most widely used to treated fungal infections are compounds that inhibit cytochrome P450-dependent C14α-demethylase (CYP51), but other enzymes of this pathway, such as squalene synthase (SQS) which catalyses the first committed step in sterol biosynthesis, could be viable targets. The aim of this study was to evaluate the antifungal activity of SQS inhibitors on Candida albicans, Candida tropicalis and Candida parapsilopsis strains. Methods: Ten arylquinuclidines that act as SQS inhibitors were tested as antiproliferative agents against three ATCC strains and 54 clinical isolates of Candida albicans, Candida tropicalis and Candida parapsilopsis. Also, the morphological alterations induced in the yeasts by the experimental compounds were evaluated by fluorescence and transmission electron microscopy. Results: The most potent arylquinuclidine derivative (3-[1'-{4'-(benzyloxy)-phenyl}]-quinuclidine-2-ene) (WSP1267) had a MIC50 of 2 μg/ml for all species tested and MIC90 varying from 4 μg/ml to 8 μg/ml. Ultrathin sections of C. albicans treated with 1 μg/ml of WSP1267 showed several ultrastructural alterations, including (a) loss of cell wall integrity, (b) detachment of the plasma membrane from the fungal cell wall, (c) accumulation of small vesicles in the periplasmic region, (d) presence of large electron-dense vacuoles and (e) significantly increased cell size and cell wall thickness. In addition, fluorescence microscopy of cells labelled with Nile Red showed an accumulation of lipid droplets in the cytoplasm of treated yeasts. Nuclear staining with DAPI revealed the appearance of uncommon yeast buds without a nucleus or with two nuclei. Conclusion: Taken together, our data demonstrate that arylquinuclidine derivatives could be useful as lead compounds for the rational synthesis of new antifungal drugs.
- 21 January 2011
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 10 (1) , 3
Open AccessSynthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis
Background: Sterol biosynthesis is an essential pathway for fungal survival, and is the biochemical target of many antifungal agents. The antifungal drugs most widely used to treated fungal infections are compounds that inhibit cytochrome P450-dependent C14α-demethylase (CYP51), but other enzymes of this pathway, such as squalene synthase (SQS) which catalyses the first committed step in sterol biosynthesis, could be viable targets. The aim of this study was to evaluate the antifungal activity of SQS inhibitors on Candida albicans, Candida tropicalis and Candida parapsilopsis strains. Methods: Ten arylquinuclidines that act as SQS inhibitors were tested as antiproliferative agents against three ATCC strains and 54 clinical isolates of Candida albicans, Candida tropicalis and Candida parapsilopsis. Also, the morphological alterations induced in the yeasts by the experimental compounds were evaluated by fluorescence and transmission electron microscopy. Results: The most potent arylquinuclidine derivative (3-[1'-{4'-(benzyloxy)-phenyl}]-quinuclidine-2-ene) (WSP1267) had a MIC50 of 2 μg/ml for all species tested and MIC90 varying from 4 μg/ml to 8 μg/ml. Ultrathin sections of C. albicans treated with 1 μg/ml of WSP1267 showed several ultrastructural alterations, including (a) loss of cell wall integrity, (b) detachment of the plasma membrane from the fungal cell wall, (c) accumulation of small vesicles in the periplasmic region, (d) presence of large electron-dense vacuoles and (e) significantly increased cell size and cell wall thickness. In addition, fluorescence microscopy of cells labelled with Nile Red showed an accumulation of lipid droplets in the cytoplasm of treated yeasts. Nuclear staining with DAPI revealed the appearance of uncommon yeast buds without a nucleus or with two nuclei. Conclusion: Taken together, our data demonstrate that arylquinuclidine derivatives could be useful as lead compounds for the rational synthesis of new antifungal drugs.